1. AR-NE3A, a New Macromolecular Crystallography Beamline for Pharmaceutical Applications at the Photon Factory
- Author
-
Yusuke Yamada, Masahiko Hiraki, Kumiko Sasajima, Naohiro Matsugaki, Noriyuki Igarashi, Yasushi Amano, Masaichi Warizaya, Hitoshi Sakashita, Takashi Kikuchi, Takeharu Mori, Akio Toyoshima, Shunji Kishimoto, Soichi Wakatsuki, R. Garrett, I. Gentle, K. Nugent, and S. Wilkins
- Subjects
Physics ,Data processing ,Data collection ,Photon ,business.industry ,Macromolecular crystallography ,Electrical engineering ,Particle accelerator ,Sample (graphics) ,law.invention ,Beamline ,law ,Factory (object-oriented programming) ,business ,Computer hardware - Abstract
Recent advances in high‐throughput techniques for macromolecular crystallography have highlighted the importance of structure‐based drug design (SBDD), and the demand for synchrotron use by pharmaceutical researchers has increased. Thus, in collaboration with Astellas Pharma Inc., we have constructed a new high‐throughput macromolecular crystallography beamline, AR‐NE3A, which is dedicated to SBDD. At AR‐NE3A, a photon flux up to three times higher than those at existing high‐throughput beams at the Photon Factory, AR‐NW12A and BL‐5A, can be realized at the same sample positions. Installed in the experimental hutch are a high‐precision diffractometer, fast‐readout, high‐gain CCD detector, and sample exchange robot capable of handling more than two hundred cryo‐cooled samples stored in a Dewar. To facilitate high‐throughput data collection required for pharmaceutical research, fully automated data collection and processing systems have been developed. Thus, sample exchange, centering, data collection, and data processing are automatically carried out based on the user’s pre‐defined schedule. Although Astellas Pharma Inc. has a priority access to AR‐NE3A, the remaining beam time is allocated to general academic and other industrial users.
- Published
- 2010